A COMPARISON OF AMPICILLIN-SULBACTAM WITH CEFOXITIN IN THE TREATMENT OF LOWER RESPIRATORY-TRACT INFECTIONS OF BACTERIAL ETIOLOGY

A COMPARISON OF AMPICILLIN-SULBACTAM WITH CEFOXITIN IN THE TREATMENT OF LOWER RESPIRATORY-TRACT INFECTIONS OF BACTERIAL ETIOLOGY

Tan J; File T M

Advances in Therapy

1994

1994-01

Ampicillin/sulbactam (1.0-2.0 g ampicillin and 0.5-1.0 g sulbactam) and cefoxitin (1.0-2.0 g), both administered intravenously once every 6 hours, were compared in patients with lower respiratory tract infections. Thirty-two of the 51 ampicillin/sulbactam-treated patients and 24 of the 49 patients who received cefoxitin were evaluable. No significant differences were noted in the clinical and bacteriologic responses to the two antimicrobials (P = .349 and P = .473, respectively). Twenty-two (68.8%) of the ampicillin/sulbactam-treated patients were cured and 9 (28.1%) were improved; there was 1 failure. Thirteen (54.2%) patients who received cefoxitin were cured and 10 (41.7%) were improved; clinical outcome in 1 patient was not able to be determined. All isolates were eradicated in 28 (87.5%) of the patients who received ampicillin/sulbactam. The original pathogen persisted in 2 (6.3%) others. The bacteriologic response was not determined in 2 (6.3%) patients. All initial isolates were eradicated in 20 (83.3%) cefoxitin-treated patients and partially eradicated in 1 (4.2%) additional patient. In 2 (8.3%) patients, the original pathogen persisted. The bacteriologic response was not determined in 1 (4.2%) patient. Adverse reactions occurred with approximately equal frequency in both groups.

ampicillin sulbactam; cefoxitin; lower respiratory tract infection; Pharmacology & Pharmacy; Research & Experimental Medicine

n/a

Journal Article

n/a

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

11-20

1

11